Biochemical treatment of peritoneal mesothelioma

Peritoneal mesothelioma (peritoneal mesothelioma) for the primary in the peritoneal epithelium and mesothelial cancer organizations, clinical rare. Can be categorized as pathological adenomatoid mesothelioma (adenomatoid mesothelioma), cystic mesothelioma (cystic mesothelioma) and malignant mesothelioma (peritoneal malignant mesothelioma, PMM).
Peritoneal mesothelioma (peritoneal mesothelioma) for the primary in the peritoneal epithelium and mesothelial cancer organizations, clinical rare. Can be categorized as pathological adenomatoid mesothelioma (adenomatoid mesothelioma), cystic mesothelioma (cystic mesothelioma) and malignant mesothelioma (peritoneal malignant mesothelioma, PMM). The first two are benign. Cystic mesothelioma more common in women, the cause is unknown, occur in the pelvic or accessories around, showing single or multiple cystic masses; patients often palpable abdominal mass due to the treatment. Malignant peritoneal mesothelioma (PMM) account for about 30% of malignant mesothelioma; its occurrence is closely related with exposure to asbestos, about 5% of patients had history of exposure; asbestos fiber intake by mouth, after translocation through the intestinal wall into the peritoneal and pleural metastasis from disease or from. From exposure to asbestos to diagnosis, the disease incubation period of up to 25 to 40 years. But the domestic 1951 ~ 1993 20 reported in the literature 161 cases of PMM in only 1 case had history of exposure to asbestos. ZHOU Ya-kang and other reported 47 cases of mesothelioma there are eight cases of malignant peritoneal mesothelioma, as well as the author collected two cases have history of exposure to asbestos. In the absence of asbestos-exposed populations, its incidence rate is about 1 person / 1 million person-years may be related to certain viral infections and genetic factors. PMM has reported 1 cases of foreign patients come into contact with more than 40 years ago, thorium dioxide colloid (Thorotrast). PMM often occurs in men over the age of 40. Visceral or parietal peritoneum can suffer from; and tumors can be a direct violation of abdominal and pelvic organs; 50% ~ 70% of patients with lymphatic and / or hematogenous metastasis of liver, kidney, adrenal gland, lung, bone and so on.

Biological response modifier therapy:

Biological response modifiers (biological response modifier, BRM) some of the body's own cells and molecules, can answer to stimulate the body's internal and external environment, and to participate in the body to maintain environmental stability. BRM through the mobilization of the inherent capacity of the body to resist and eliminate cancer, become the new mode of treatment of cancer. With the cell engineering and genetic engineering progress, BRM come in handy in the field of cancer therapy.

Cytokines: interleukin (IL), interferon (IFN), tumor necrosis factor (TNF), etc. In addition to direct anti-tumor cells, and can be activated in vivo anti-cancer cells, or secretion of anti-cancer effects of molecules, or maintain the immune response cell proliferation and differentiation features, PMM can be used as adjuvant therapy.

Adoptive transfer of immune cells: collection, separation of malignant ascites in the lymphocytes, in vitro expansion, and induces cytotoxicity issued Lymphokine Activated Killer cells (LAK cells) and integrate it into the body, there are anti-tumor cells. At the same time to give IL-2, can improve efficacy. Tani and so will the patient's own lymphocytes and malignant mesothelioma cells in mixed culture, to be anti-monoclonal antibody and IL-2 activation of the generated cytotoxic T cells (CTL). Activated CTL against malignant mesothelioma cells have a high degree of self-cytotoxicity. PMM to the two cases reported in the literature, while patients with chemotherapy, intra-abdominal injection of CTL as an auxiliary therapy, the results of ascites subsided gradually disappeared tumor blocks, improving the patient's quality of life.